Assessment of Plasminogen Activator Inhibitor- 1(PAI1) In Children with hemophilia A.

Abd-Elhalim, Sahar Salah; Hussien, Amany Korany; Abdel Rahman, Aya Ahmad; Morgan, Dalia Saber

doi:10.21608/ejmr.2025.384399.1830

Assessment of Plasminogen Activator Inhibitor- 1(PAI1) In Children with hemophilia A.

Document Type : Original Article

Authors

¹ Pediatrics department, Faculty of Medicine, Beni-Suef University, Egypt.

² Pediatrics department Health, Insurance hospital, Benisuef, Egypt.

³ Clinical Pathology department, Faculty of Medicine, Beni-Suef University, Egypt

10.21608/ejmr.2025.384399.1830

Abstract

Deficiency of coagulation factor VIII causes the x-linked recessive condition known as hemophilia A. This investigation aims to establish a correlation among PAI-1 and the severity of bleeding in hemophiliac children. Twenty-five children with hemophilia A and twenty-five typically developing children served as subjects in a case control study. After carefully examining the data, we found that the PAI-1 Level was significantly lower in the cases group contrasted with the control group. Furthermore, a negative connection (r=-0.616, p<0.001) was found among the PAI-1 Level as well as the ISTH-BAT score, determined by the International Society of Thrombosis as well as Hemostasis-Bleeding Assessment Tool. Because PAI-1 level is a great predictor of hemophilia, we concluded that it was lower in haemophilia A patients in contrast to healthy controls.

Keywords

Main Subjects

Internal medicine ·

References

1. Müller, J., Miesbach, W., Prüller, F., Siegemund, T., Scholz, U., & Sachs, U. J. (2022). An update on laboratory diagnostics in haemophilia A and B. Hämostaseologie, 42(04), 248-260.
2. Raso, S., Lambert, C., Boban, A., Napolitano, M., Siragusa, S., & Hermans, C. (2020). Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia? Haemophilia, 26(1), 117-121.
3. Pezeshkpoor, B., Oldenburg, J., & Pavlova, A. (2022). Insights into the molecular genetic of hemophilia A and hemophilia B: the relevance of genetic testing in routine clinical practice. Hämostaseologie, 42(06), 390-399.
4. Gholami, M. S., Valikhani, M., Dorgalaleh, A., Mousavi, S. H., & Pezeshkpoor, B. (2018). Hemophilia A. Congenital Bleeding Disorders: Diagnosis and Management, 103-137.
5. Semeraro, F., Mancuso, M. E., Ammollo, C. T., Dirienzo, L., Vitulli, A., Santagostino, E., ... & Colucci, M. (2020). Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 18(2), 381-389.
6. Grabowski, E. F., Van Cott, E. M., Bornikova, L., Boyle, D. C., & Silva, R. L. (2020). Differentiation of patients with symptomatic low von Willebrand factor from those with asymptomatic low von Willebrand factor. Thrombosis and Haemostasis, 120(05), 793-804.
7. Kim, J. Y., & You, C. W. (2019). The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood research, 54(3), 204-209.
8. Mochizuki, L., Sano, H., Honkura, N., Masumoto, K., Urano, T., & Suzuki, Y. (2023). Visualization of Domain-and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis. Thrombosis and haemostasis, 123(01), 016-026.
9. Duque, P., Mora, L., Levy, J. H., & Schöchl, H. (2020). Pathophysiological response to trauma-induced coagulopathy: a comprehensive review. Anesthesia & Analgesia, 130(3), 654-664.
10. Vercauteren, E., Gils, A., & Declerck, P. J. (2013, June). Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. In Seminars in thrombosis and hemostasis (Vol. 39, No. 04, pp. 365-372). Thieme Medical Publishers.
11. Bouton, M. C., Geiger, M., Sheffield, W. P., Irving, J. A., Lomas, D. A., Song, S. & Lucas, A. R. (2023). The under‐appreciated world of the serpin family of serine proteinase inhibitors. EMBO Molecular Medicine, 15(6), e17144.
12. Hazendonk, H. C. A. M., van Moort, I., Mathôt, R. A. A., Fijnvandraat, K., Leebeek, F. W. G., Collins, P. W., ... & OPTI-CLOT study group. (2018). Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. Blood reviews, 32(4), 265-271.
13. Minhas, A., Younas, A., Eiman, H., Rasool, I., Fatima, M., Imran, A., & Chughtai, A. S. (2023). The Role of ISTH Bleeding Assessment Tool in Diagnosing Patients with Suspected Bleeding Disorders. Journal of Haematology and Stem Cell Research, 3(2), 94-98.
14. Shahbazi, M., Ahmadinejad, M., & Teimourpour, A. (2024). Utility of the international society on thrombosis and hemostasis-bleeding assessment tool in the diagnosis of patients who suspected of platelet function disorders. Blood Coagulation & Fibrinolysis, 35(1), 8-13.
15. Chaves, D. G., da Silva Santos, B. A., Zucherato, L. W., Dias, M. M., Lorenzato, C. S., de Oliveira, A. G., ... & Rezende, S. M. (2024). High levels of anti–factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors. Research and Practice in Thrombosis and Haemostasis, 8(4), 102436.
16. Moretti, L., Bizzoca, D., Buono, C., Ladogana, T., Albano, F., & Moretti, B. (2021). Sports and children with hemophilia: Current trends. Children, 8(11), 1064.
17. Hassab, H. M., Saad, H. R., & Abdel Ghany, H. M. (2022). Quality of life and clinical assessment of joint health in children with hemophilic arthropathy. Egyptian Rheumatology and Rehabilitation, 49(1), 22.
18. Soliman, M., Osman, N., Hefnawy, S., & El Hawy, M. A. (2022). Assessment of plasminogen activator inhibitor-1 (PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A. Pediatric Hematology and Oncology, 39(4), 318-328.
19. Rehill, A. M., McCluskey, S., O'Donnell, J. S., Dockal, M., Preston, R. J., & iPATH Study Group. (2021, March). Heterogeneity in bleeding tendency and arthropathy development in individuals with hemophilia. In Seminars in Thrombosis and Hemostasis (Vol. 47, No. 02, pp. 183-191). Thieme Medical Publishers, Inc.
20. Roy, S., & De, A. K. (2019). Effect of prophylactic management of hemophilia on bleeding episodes. Indian Journal of Hematology and Blood Transfusion, 35(3), 496-501.
21. Xue, F., Dai, J., Chen, L. X., Liu, W., Zhang, H. Q., Wu, R. H., ... & Yang, R. C. (2024). Report on the diagnosis and treatment of hemophilia in China (Version 2024). LabMed Discovery, 100007.
22. Dahlbäck, B., & Villoutreix, B. O. (2005). Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arteriosclerosis, thrombosis, and vascular biology, 25(7), 1311-1320.
23. Heiman, M., Gupta, S., Lewandowska, M., & Shapiro, A. D. (2017). Complete plasminogen activator inhibitor 1 deficiency.
24. Olsson, A. (2016). Bleeding tendency and health-related quality of life in carriers of haemophilia.
25. Saes, J. L., Verhagen, M. J., Meijer, K., Cnossen, M. H., Schutgens, R. E., Peters, M., ... & Schols, S. E. (2020). Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood advances, 4(20), 5025-5034.